These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 16502833)
21. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Emkey RD; Ettinger M Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937 [TBL] [Abstract][Full Text] [Related]
22. [Stability also depends on other parameters. Bone density--not a good indicator for fracture prevention]. MMW Fortschr Med; 2004 Aug; 146(31-32):53. PubMed ID: 15529718 [No Abstract] [Full Text] [Related]
23. Recognition of women at risk for fracture and intervention with fast-acting therapies. Derman R Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104 [TBL] [Abstract][Full Text] [Related]
24. Osteoporosis: handy tools for detection, helpful tips for treatment. Morgan SL; Kitchin B J Fam Pract; 2008 May; 57(5):311-20. PubMed ID: 18460296 [No Abstract] [Full Text] [Related]
25. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis]. Wada S; Fukawa T; Kamiya S Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665 [TBL] [Abstract][Full Text] [Related]
26. [Therapy of osteoporosis with bisphosphonate. Bone quality maintained over years]. MMW Fortschr Med; 2003 Jun; 145(23):59. PubMed ID: 12854232 [No Abstract] [Full Text] [Related]
28. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009 [TBL] [Abstract][Full Text] [Related]
29. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women]. Gorai I; Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077 [TBL] [Abstract][Full Text] [Related]
30. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Cramer JA; Silverman S Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936 [TBL] [Abstract][Full Text] [Related]
32. ["European Guidance 2008" for the diagnosis and management of postmenopausal osteoporosis--what is new and clinically relevant?]. Bartl R; Dtsch Med Wochenschr; 2009 Jan; 134(3):92-4. PubMed ID: 19142840 [No Abstract] [Full Text] [Related]
33. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly]. MMW Fortschr Med; 2006 Jun; 148(25):60-1. PubMed ID: 16859169 [No Abstract] [Full Text] [Related]
34. [Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy]. Xiu Bing-He ; Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):876-9. PubMed ID: 24447490 [No Abstract] [Full Text] [Related]
35. [Treatment of osteoporosis. Not only measurements count]. MMW Fortschr Med; 2002 Sep; 144(35-36):56. PubMed ID: 12380363 [No Abstract] [Full Text] [Related]
36. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Gold DT; Alexander IM; Ettinger MP Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667 [TBL] [Abstract][Full Text] [Related]
37. Is treatment of early postmenopausal women with bisphosphonates justified? Epstein S Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359 [TBL] [Abstract][Full Text] [Related]
38. [Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice]. MMW Fortschr Med; 2007 Mar; 149(13):50. PubMed ID: 17672400 [No Abstract] [Full Text] [Related]
40. [New bone density conservation agents for osteoporosis under research and development: Minodronic acid]. Takata S Nihon Rinsho; 2007 Nov; 65 Suppl 9():417-20. PubMed ID: 18161142 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]